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Inhibition of neointimal hyperplasia in a sheep
model of dialysis access failure with the
bioabsorbable Vascular Wrap paclitaxel-eluting
mesh
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MDc Seattle, Wash; and Vancouver, British Columbia, Canada
Objective: This study evaluated the effect of a bioabsorbable mesh containing paclitaxel on neointimal hyperplasia in a
sheep model of dialysis access failure.
Methods: Forty neutered male sheep were randomized to one of five parallel groups: no mesh; or a 3-cm 6-cmmesh with
0.0, 0.3, 0.7, or 1.2g/mm2 of paclitaxel for a total dose of 0.0, 0.6, 1.3, or 2.2 mg, respectively. Commercially available
6-mm internal diameter expanded polytetrafluoroethylene grafts were surgically placed between the left common carotid
artery and the right external jugular vein. For those animals randomized to one of the mesh groups, the mesh was placed
around the distal end of the graft and venous anastomosis. Patency was assessed at weekly intervals throughout the study.
Animals were euthanized 8 weeks after implantation, and grafts and veins were harvested. After histologic processing, six
cross sections were cut at the venous end of the graft and vessel. The primary and secondary efficacy outcome measures,
respectively, were the area and capillary density of the neointima at the graft-vein anastomosis. Histologic analyses were
also performed to investigate the effects of the paclitaxel-eluting mesh on the anastomotic site.
Results: Grafts occluded before the scheduled sacrifice in five animals, and they were excluded from the study and not
replaced. Control animals developed significant neointimal hyperplasia at the cross section taken perpendicular to the
graft at its most distal end: the neointimal area measured 10.5  6.8 mm2 in the no mesh group and 6.4  3.2 mm2 in
the zero-dose mesh group (P .28). In contrast, neointimal area was significantly reduced in the paclitaxel mesh groups:
0.9  1.4 mm2 in the 0.3 g/mm2 group (P  .008 vs zero-dose mesh), 1.3  1.5 mm2 in the 0.7 g/mm2 group (P 
.004 vs zero-dose mesh), and 1.2  1.4 mm2 in the 1.2 g/mm2 group (P  .008 vs zero-dose mesh). Capillary density
in the neointima at the graft-vein anastomosis decreased with paclitaxel and was significantly reduced in the paclitaxel
mesh groups with 0.3 and 1.2 g/mm2 compared with the zero-dose mesh control (3.6 2.9 vs 8.9 5.6 per mm2 [P
.022] and 1.1  1.7 vs 8.9  5.6 per mm2 [P  .001] respectively). The paclitaxel mesh had no significant effect on
healing of the anastomosis or on the thickness of the adjacent vein.
Conclusions: In this model, the paclitaxel-eluting mesh significantly reduced neointimal hyperplasia and neointimal
capillary density without apparent toxicity to the adjacent vein. (J Vasc Surg 2007;45:1029-38.)
Clinical Relevance: Although synthetic grafts (most commonly expanded polytetrafluoroethylene) are currently used in
approximately 40% of hemodialysis patients who require a permanent vascular access, primary patency rates remain poor.
Most graft failures are caused by venous neointimal hyperplasia, and there are no proven pharmacologic interventions
that effectively prevent it. This study provides evidence of the safety and efficacy of a bioabsorbable paclitaxel-eluting
mesh for inhibition of neointimal hyperplasia in a sheep model of dialysis access graft failure.From the Veteran Affairs Puget Sound Health Care System, University of
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doi:10.1016/j.jvs.2007.01.057Maintenance of arteriovenous (AV) access is one of the
most intractable issues in the management of hemodialysis
patients.1 Native AV fistulas, used in 43.7% of long-term
hemodialysis patients in the United States as of August
2006,2 have repeatedly proven to be superior to all other
forms of dialysis access, both clinically and in cost effective-
ness.3 Accordingly, there is a concerted and ongoing effort
underway in the United States (US) to encourage the
placement of native AV fistulas for dialysis access whenever
possible.4 Inmany cases, however, it is not feasible to create
a primary AV fistula, particularly in older, diabetic patients
and in patients whose veins have been used for multiple
venipunctures and intravenous infusions over the course of
their prolonged illness.
Synthetic grafts, most commonly made from expanded
polytetrafluoroethylene (ePTFE), are required when no
suitable vein is available for fistula creation. Synthetic grafts
have worse patency rates of 50% at 1 year and 25% at 2 years
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Despite this, approximately 39% of US hemodialysis pa-
tients—or roughly 116,000 patients—had a synthetic graft
placed for vascular access in 2004. Synthetic vascular grafts
have significant advantages over native fistulas: they are
easier to create and cannulate, and they require less time to
mature (2 weeks vs 2 months). These devices are preferred
over central catheters, which have a high rate of infection
and may produce central vein stenosis.
Eighty percent of PTFE grafts fail because intimal
hyperplasia causes stenosis at the venous anastomosis.6 If
this problem could be eliminated or significantly mitigated
to provide patency rates similar to native AV fistulas, then
themany advantages of PTFEwouldmake this an attractive
option in many more patients. To date, no therapies are
available to effectively inhibit intimal hyperplasia at the
venous anastomosis. Angioplasty is not a durable treat-
ment,7-9 and repeat multiple procedures are often neces-
sary.5,6 Many systemically delivered drugs have been found
to reduce intimal hyperplasia in various animal models of
restenosis after vascular injury, but none have proven to
have clinical benefit (eg, heparin, angiotensin-converting
enzyme inhibitors, calcium channel blockers, steroids).
Similarly, no systemic pharmacologic interventions to date
have proven effective in the prevention or treatment of
venous intimal hyperplasia in ePTFE dialysis grafts, al-
though dipyridamole has shown some promise.3,10,11
In contrast, certain pharmacologic agents combined
with a local intravascular delivery device are effective in
reducing neointimal formation in other vascular applica-
tions. One such combination, the paclitaxel-eluting stent
used in coronary angioplasty, has proven highly successful
in preventing restenosis and major adverse coronary
events.12-17 Even though the drug remains active for only a
few weeks, the benefits of this therapy are durable, persist-
ing for as long as 4 years.18 A similar, local therapy approach
would be very attractive for dialysis access grafts, particu-
larly if it had no adverse effect on healing and could be
applied easily at the time of surgery. The Vascular Wrap
(Angiotech Pharmaceuticals, Inc, Vancouver, British Co-
lumbia, Canada) was developed for this purpose. It is a
mesh containing paclitaxel and is composed of polygly-
colic-polylactid acid, which fully degrades by hydrolysis
in vivo between 60 to 90 days. We tested this local ther-
apy in a well-characterized sheep model of dialysis access
stenosis.19
METHODS
Experimental design and conduct. The in-life com-
ponent of the study was conducted at the research facility of
BioDevelopment Associates, LLC (Bellevue, Wash) and
was approved for compliance with regulatory guidelines
concerning the care and use of animals by its Institutional
Animal Care andUse Committee. The facility is licensed by
the US Department of Agriculture and approved by the
Office for Protection From Research Risks. All animal
housing and care complied with theGuide for the Care and
Use of Laboratory Animals (US National Institutes ofHealth Publication No. 85-23, National Academy Press,
Washington, DC, revised 1996).
After the administration of heparin (150 U/kg intra-
venously [IV]), commercially available ePTFE grafts (Im-
pra Flex ePTFE Vascular Grafts, 6 mm internal diameter,
Bard Peripheral Vascular, Inc, Tempe, Ariz) approximately
8 cm in length were placed between the left common
carotid artery and right external jugular vein in 40 sheep,
one per animal. Animals were randomized (8 per group) to
one of five treatment groups: no mesh; or mesh with 0.0,
0.3, 0.7, or 1.2 g/mm2 of paclitaxel, for a respective total
dose of 0.0, 0.6, 1.3, or 2.2 mg. For those animals in the
mesh groups, a sterilized 3-cm  6-cm paclitaxel-eluting,
bioabsorbable mesh was placed around the distal end of the
graft-vein anastomosis. Surgeons applying the mesh were
blinded to treatment group.
Graft patency was assessed immediately after implanta-
tion and at weekly intervals thereafter. Animals were eutha-
nized 8 weeks after implantation and grafts and veins were
harvested. After histologic processing, six cross sections
were cut at the graft-vein anastomosis (Fig 1). Histopatho-
logic and morphometric analyses of these samples were
performed by a pathologist who was blinded to the treat-
ment group of each animal.
Experimental procedures. In vitro release profiles for
paclitaxel were obtained by placing samples of the mesh in
a culture tube with phosphate buffer (pH 7.4) containing
bovine albumin (0.8 g/L). The tubes were placed on a
rotating disk (Glas-Co, Terre Haute, Ind) at 37°C. The
amount of drug eluting into solution was assayed at various
times up to 10 days. At these times, the buffer was removed
from the sample and replaced with fresh buffer. The drug
was extracted from the removed solution with 1 mL of
dichloromethane, which was then separated from the sam-
ples by pipetting. After addition of a 1:1 acetonitrile and
water solution, the paclitaxel content was analyzed by
high-performance liquid chromatography. Results were
calculated as the cumulative percentage of paclitaxel eluting
Fig 1. Schematic diagram of right external jugular vein and ex-
panded polytetrafluoroethylene (ePTFE) graft anastomosis with
applied mesh and histologic sections.over time.
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(Nebeker Ranch, Los Angeles, Calif), neutered for ease of
handling, were fasted for 12 hours before surgery and then
sedated with intramuscular xylazine (0.2 to 1.0 mg/kg)
and IV ketamine (3 to 10 mg/kg). After intubation, anes-
thesia was maintained with inhalation isoflurane. The neck
was prepared for aseptic surgery.
Expanded PTFE grafts (6-mm internal diameter) were
placed between the left common carotid artery and right
external jugular vein, as reported previously.19 After graft
placement and restoration of blood flow, the vessels were
allowed to equilibrate for several minutes. For those ani-
mals randomized to receive a mesh, the mesh was then
applied to the distal (venous) anastomosis by pulling the
long side (6 cm) of the mesh under the vein and up around
either side of the distal end of the graft. One edge of the
mesh was positioned as close to the heel of the anastomosis
as possible. Sutures were placed at the proximal and distal
ends of the mesh and sewn to nearby connective tissue to
prevent slippage. The surgical site was then closed in layers.
Animals were administered flunixin meglumine (Bana-
mine [Schering-Plough, Kenilworth, NJ], 1.0 mg/kg in-
tramuscularly or subcutaneously as needed) as an analgesic
to relieve postoperative pain. In addition, intramuscular
ampicillin (5 mg/kg) was administered for 3 days begin-
ning the day of the surgery.
Animals were fed daily PMI Rumilab Diet (PMI Nutri-
tion International, LLC Brentwood, Mo). They were
group-housed in wire-mesh enclosed pens with concrete
floors for 4 to 10 days after surgery and were thenmoved to
a fenced pasture with readily available shelter and supple-
mental feed, as described.
Immediately after implantation and at weekly intervals
thereafter, graft patency was assessed by palpation or aus-
cultation, or both, with a stethoscope for evidence of blood
flow through the graft. Animals with graft failure occurring
before the scheduled sacrifice were euthanized after confir-
mation of occlusion using Doppler ultrasonography and
angiography. The remaining animals were euthanized be-
tween 56 and 58 days after graft implantation. Animals
were sedated with intramuscular xylazine (0.2 to 1.0 mg/
kg) and IV ketamine (3 to 10 mg/kg), intubated, and
anesthetized with isoflurane. Contrast medium was in-
jected through puncture of the midgraft, and angiograms
were taken of the graft and vein at the distal anastomosis to
verify patency. Animals received heparin (150 U/kg, IV)
and were euthanized with an IV overdose of sodium pen-
tobarbital.
The artery was immediately cannulated proximal to the
arterial anastomosis and ligated beyond it. The recipient
vein was opened to allow drainage, and the ePTFE graft
was rinsed in situ with Ringer’s lactate solution, followed by
10% neutral buffered formalin at physiologic pressure for
several minutes. The specimens were excised and allowed to
immersion-fix in formalin for a minimum of 24 hours
before histologic processing. Six samples were then cut at
the graft-vein anastomosis (Fig 1). Adjacent samples were
cut at intervals of 2.5 to 4.5 mm. Specimens were paraffin-embedded, and cut as thin sections for histology. Slides
were stained with hematoxylin and eosin. The study pathol-
ogist performed all qualitative and quantitative analyses in a
blinded fashion. Assessment of the blinded histopathology
observations relative to treatment group assignation was
performed retrospectively.
Outcome measures. Histopathologic assessment in-
cluded characterization of cellular composition of vascular
and perivascular tissue and graft in the vicinity of the venous
anastomosis. Efficacy was measured by morphometric anal-
ysis of the cross-sectional samples. Quantitative analyses
were made with computer-aided morphometry using Im-
age-Pro Plus 4.5.1.22 (Media Cybernetics, Silver Spring,
Md) for Windows XP (Microsoft, Redmond, Wash).
Morphometric measurements included the combined
area of neointima and mural thrombus and area inside the
graft (Appendix A, online only); the pathologist then used
these measurements to calculate values for neointimal area
and luminal area. Percentage of stenosis was calculated as
the ratio of the luminal area to the area inside the graft. For
these morphometric outcomes, section 5, cut from the
graft at its distal (venous) end, was determined to be the
cross-section of primary interest because it was the most
proximate to the anastomosis. Data are also reported for
the adjacent graft section (section 6), approximately 5 mm
upstream from the venous anastomosis. Neointimal area
was chosen as the primary efficacy end point because it is
the most accurate measure of neointimal hyperplasia.
Because paclitaxel inhibits angiogenesis as well as cel-
lular proliferation, capillary density was measured to deter-
mine if reduction in neointimal hyperplasia was associated
with a reduction in neovascularization. Capillary density
was measured in the neointima within the PTFE graft at the
toe of the graft (section 4 or 3, whichever had the best arc
of ePTFE graft with adjacent vein). The toe section was
chosen because it is closest to the vein and has the most
abundant capillary ingrowth. For this calculation, capillar-
ies were identified and counted using sections stained with
hematoxylin and eosin under light microscopy, using up to
original magnification400 as needed (Fig 2). The density
was then calculated as the number of capillaries per mm2 of
neointima.
Statistical considerations. Animals whose grafts oc-
cluded before the scheduled sacrifice were excluded from
the analysis. Histopathologic features were evaluated using
a graded severity scale for semi-quantitative analysis. Re-
sults from the morphometric analyses were tabulated, and
group means and standard deviations were calculated. A
nonparametric approach was used rather than a parametric
approach owing to the small sample size and the observa-
tion that the variance was inhomogeneous (see Results).
Several transformations of the data were performed, but
none were used because they still yielded large differences
in standard deviations.
Nonparametric tests were used to compare groups.
Specifically, pair-wise Fligner-Policello (FP) tests were used
for the comparisons of interest. This test is similar to a
Wilcoxon rank sum test but uses the Behrens-Fisher mod-
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different.20 Because standard tables for the FP test statistic
only provide ranges of P values, exact two-sided Wilcoxon
rank sum P values were also computed for all comparisons.
Note that although the Wilcoxon P values are significant at
the .05 level, standard FP tables only provide one-sided P
values and thus a significant result is obtained only if the
absolute value of the test statistic is greater than the critical
value corresponding to /2  .025. For simplicity of
presentation, only theWilcoxon P values are reported in the
tables, figures, and text; the corresponding FP test statistics
are provided in Appendices B and C (online only).
For each cross-section of interest, the zero-dose mesh
group was compared with the control group with no mesh.
All paclitaxel-loaded mesh groups were then compared
with the zero-dose mesh group. The two graft cross sec-
tions, sections 5 and 6, cut from the graft at its distal
(venous) end, were determined to be the cross sections of
primary and secondary interest, respectively. The Fisher
exact test was used to compare patency of control and
drug-treated grafts. Linear regression analyses of the neo-
intimal area and capillary density were also performed.
RESULTS
The in vitro drug elution profile of paclitaxel from the
mesh at 0.3, 0.7, and 1.2 g/mm2 is shown in Fig 3. There
was a rapid release of drug during the first 24 hours,
followed by a more gradual release over the next 8 days.
The rates of release increased with increasing drug concen-
tration. At 1 week, 60% of the drug was released in the
lower two concentrations (0.3 and 0.7 g/mm2), and 45%
of the drug was released from the highest-dose mesh.
Animals appeared in good health and gained weight
across all groups throughout the study. The average weight
at the time of surgery was 35.5 kg. Surgical implantations of
AV grafts, with and without mesh, were performed without
Fig 2. Example of a section through the toe of the graft
measured in the neointima (bar represents 4 mm). The i
demonstrating multiple capillaries (arrow).complication or death.Grafts occluded in five sheep before the scheduled
sacrifice. Three of the five treatment groups were repre-
sented among the early occlusions: one graft in the zero-
dose mesh group occluded after week 6; two grafts in the
0.3 g/mm2 paclitaxel mesh group occluded after week 3
or 4; and two grafts in the 1.2 g/mm2 paclitaxel mesh
group occluded after week 3. In one animal in the 0.3
g/mm2 paclitaxel mesh group, the graft had eroded
through the skin at its midsection, resulting in a kink that
obstructed flow. The incisions in this animal were well
healed, and there was no gross evidence of infection. The
remaining four animals all had occlusive thrombi with no
discernible cause.
A two-tailed Fisher exact test found no statistically
significant difference between the proportions of grafts
with occlusion in the drug group (16.7%) vs the control
group (6.3%, P  0.63). Necropsies performed on the 35
animals with patent grafts at 8 weeks indicated that inci-
sions were well healed, with no evidence of inflammation.
Healing around the venous anastomosis was normal in all
animals, with mild-to-moderate fibrotic encapsulation of
the graft.
Histologic analysis. Compared with the no-mesh
control group, the addition of mesh alone resulted in an
increase in the thickness of the fibrous tissue encapsulating
the graft (from 0.8 mm to 1.5 mm) and an increase in
perigraft macrophages fromminimal to mild. Macrophages
were concentrated around disintegrating mesh debris.
Among groups that received paclitaxel, there was more
mesh debris at higher paclitaxel doses and fewer macro-
phages. In the no-mesh and mesh-alone control groups,
the nodes of the graft wall were completely filled with
spindle-shaped cells (presumably myofibroblasts). In con-
trast, almost no spindle-shaped cells were found in the
nodes of the graft wall in the highest paclitaxel dose group;
ion 4) at low power showing where capillary density was
a high power (bar represents 400 m) from this region(sect
nset isonly degenerating blood and fibrin debris were present.
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perigraft inflammation or on the process of endothelializa-
tion (cells with the histologic appearance of endothelium
covered the neointima in all groups). There was some
enlargement of the vein at the anastomosis in most cases
and some thickening of the vein; this was evident across all
treatment groups. There was no evidence of loss of integrity
of the vein wall at any dose. As we have found in our earlier
work with this model, the vein adjacent to the graft did not
develop hyperplasia.19 Sections 1, 2, 3, and 4, taken
through the vein, revealed no apparent atrophy or decrease
in vein wall thickness, no surface thrombus, and an appar-
ently intact endothelial lining (although immunohisto-
chemistry was not performed for definitive cell typing).
Morphometric analysis. The nonparametric ap-
proach to data analysis was justified by the observation that
the variance was very inhomogeneous among the groups as
assessed visually using box plots. Although no official test-
ing for unequal variances was performed, the standard
deviation for the untransformed data for one group was
often 10 times the standard deviation for another group in
the same section.
At section 5, the first cross section through the graft
above the anastomosis, neointimal hyperplasia was exten-
sive in the group with no mesh and the group with zero-
dose mesh (Table, Fig 4). Neointimal area was significantly
lower in all paclitaxel mesh groups compared with the
zero-dose mesh group (P  .008); sample photomicro-
graphs illustrating this difference are presented in Fig 5.
Section 6 had less neointima than section 5, but the effects
Fig 3. In vitro drug elution curves (presented with mea
polylactid acid mesh at the three concentrations used
(triangles) g/mm2.of paclitaxel were similar (Fig 4, Appendix C. online only).Similar trends were observed for the outcomes of mural
thrombus area and percentage of stenosis in both sections
(Table; Appendices B and C, online only). Capillary density
in the neointima at the graft-vein anastomosis (section 4 or
3) also decreased with paclitaxel (Table; Appendix B, on-
line only). It was significantly lower in the mesh groups
with 0.3 g/mm2 and 1.2 g/mm2 paclitaxel compared
with the zero-dose group (P .022 and P .001, respec-
tively). Linear regression analyses found an inverse relation-
ship between neointimal area inside the graft and drug dose
(r2 0.85) and between capillary density in the neointima
and drug dose (r2  0.77). There was a strong, significant
relationship between capillary density and intimal area
(r2  0.99, P  .01).
DISCUSSION
In this study, application of a paclitaxel-eluting absorb-
able mesh to the distal end of ePTFE arteriovenous grafts
nearly eliminated neointimal hyperplasia at 8 weeks in a
sheep model of access failure. The mesh is a proprietary
biodegradable copolymer that resorbs in approximately 2
to 3 months and elutes paclitaxel over 21 days (approxi-
mately half 7 days). This type of local therapy has the
advantage of being easily applied at the time of surgery and
having no systemic effects. In prior experiments using
similar implantations of mesh with paclitaxel in an arterial
position, we found no detectable systemic levels of pacli-
taxel even at doses as high as 1.2 mg (unpublished data).
The dose required for local drug therapy (2 mg, eluted
standard deviation) for paclitaxel from the polyglycolic-
is experiment, 0.3 (diamonds), 0.7 (squares), and 1.2n 
in thover a period of weeks) is more than 140 times lower than
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patient.
Paclitaxel, which acts by stabilizing microtubules, in-
hibits smooth muscle cell proliferation and angiogene-
sis.21-24 This may explain the relative lack of myofibroblasts
within the wall of drug-treated grafts. We also found that
capillary density within the neointima was reduced with
paclitaxel; thus, we have demonstrated an association be-
tween capillary density and neointimal mass.
Inhibition of angiogenesis is an effective approach to
Table. Morphometric data at the graft-vein anastomosis*
Group
Neointimal area
(mm2) P†
Mural
area
No mesh (n  8) 10.5  6.8 2.6
Paclitaxel mesh (g/mm2)
0.0 (n  7) 6.4  3.2 .28‡ 3.8
0.3 (n  6) 0.9  1.4 .008§ 0.2
0.7 (n  8) 1.3  1.5 .004§ 1.5
1.2 (n  6) 1.2  1.4 .008§ 0.6
*Neointimal area, mural thrombus area, and luminal stenosis were measure
end; capillary density was measured in the neointima at the toe of the gra
presented as means  standard deviation
†All P values are based on pair-wise comparisons made using the Wilcoxon r
reported in Appendix B.
‡P vs no mesh.
§P vs mesh with 0 mg paclitaxel.
Fig 4. Dose effect of paclitaxel on neointimal area (presented
with mean  SEM). *P  .05 vs 0 mg mesh group; there was no
neointima formation with the two highest-dose mesh groups in
graft section 6. All P values reported are based on pair-wise
comparisons made using the Wilcoxon rank sum test; the ranges of
P values based on the Fligner-Policello test statistic are reported in
Appendices B and C, online only.reducing the growth of tumors, which cannot grow beyondthe limits of their blood supply. Although the results of the
current study suggest a similar relationship for inhibition of
intimal hyperplasia development in arterial venous grafts,
additional studies will be required to demonstrate a causal
relationship. It is also possible that neointima is reduced by
inhibition of smooth muscle cell proliferation and that the
reduced capillary density simply is a result of a decrease in
neointimal mass. Because of the long time course of drug
elution and the differential release rate of drug based on
drug concentration, it is not possible to assess the associa-
tion between drug dose and angiogenesis in these studies.
Dose-effect relationships would be more appropriately
studied in experiments using a series of systemic doses of
drug.
Paclitaxel is known to inhibit neutrophil and lympho-
cyte activation.25,26 Although themesh was associated with
an increase in the general inflammatory response in the
surrounding tissues, there were fewer macrophages within
the mesh debris in the paclitaxel groups. There was also
more mesh debris in the paclitaxel groups, suggesting that
the drug’s anti-inflammatory effects affected the normal
foreign body response to the mesh, thus retarding its
degradation and absorption. There was no evidence of
toxicity to the vein or disruption of the anastomoses by
paclitaxel, which is nontoxic to cells that are not proliferat-
ing. If anything, the adjacent vein was slightly thickened in
the drug-treated groups and in no case was the vein atro-
phied or aneurysmal. The absence of infections in this study
suggests that the anti-inflammatory effects of paclitaxel did
not predispose to sepsis.
There has been recent concern that drug-eluting stents
in the coronary circulation may be associated with small
increases in the rate of thrombosis. Yet, a recently presented
meta-analysis of data from 3506 patients (Martin B. Leon,
Transcatheter Cardiovascular Therapeutics, Eighteenth
Annual Scientific Symposium, October 24, 2006) demon-
strated freedom from stent thrombosis at 4 years of 99.1%
for those who had received bare metal stents and 98.7% for
bus
2) P†
Luminal stenosis
(%) P†
Capillary
density
(per mm2) P†
49.4  22.4 11.9  5.8
.40‡ 40.9  14.1 .87‡ 8.9  5.6 .28‡
.002§ 3.6  4.3 .001§ 3.6  2.9 .02§
.071§ 9.9  10.0 .001§ 4.6  6.0 .07§
.008§ 6.8  5.6 .001§ 1.1  1.7 .001§
ction 5, the cross section taken perpendicular to the graft at its most distal
tions 4 or 3, whichever had the best arc with the adjacent vein). Data are
m test; the ranges of P values based on the Fligner-Policello test statistic arethrom
(mm
 1.9
 2.9
 0.3
 2.3
 1.2
d in se
ft (sec
ank suthose who had received paclitaxel-eluting stents (P .29).
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drug-treated grafts in our study was significant, suggesting
that if anything, the drug reduces thrombosis in this set-
ting. Four of the five graft occlusions that occurred were in
the drug-treatment group, but this was not a statistically
significant association. Our 12.5% graft occlusion rate (5/
40) is similar to the 21% failure rate we observed in our
initial description of this model.19 At least one of the
failures in the current study was technical due to kinking of
the graft. The observed graft occlusions occurred at an early
time (between 4 and 5 weeks) when intimal hyperplasia is
very unlikely to have been the cause. This observation, plus
the finding of reduction in thrombus in grafts at 8 weeks,
suggests that most of the graft failures were due to technical
causes, most likely kinking, which is difficult to avoid in the
long and flexible neck of sheep.
Study limitations. No animal models exactly mimic
the clinical problem of dialysis access failure, but the sheep
model used in this study has been well characterized.19 It
develops a lesion of intimal hyperplasia that is very similar to
that found in failed human access grafts. Both have the
characteristics of neointimal hyperplasia that results from
any vascular injury. Macrophages are common surrounding
the ePTFE graft anastomosis, and smooth muscle cell
proliferation, matrix deposition, and angiogenesis are
prominent responses within the neointima.27,28 The main
differences between the sheep model and clinical access
failure are the very rapid development of the stenotic lesion
(although some patients form stenosing neointima very
rapidly), the prominence of luminal thrombus, and the
relatively large size of the vein. The sheep jugular vein is
about twice the diameter of the usual, 3-mm to 4-mm
antecubital vein used in patients, which may explain why
there is less vein wall thickening than is seen in clinical
Fig 5. Left, Photomicrograph of a representative sectio
paclitaxel mesh group (bar represents 4 mm). M, Mesh,
lumen.specimens. Turbulence and shear resulting from high flowrates are more rapidly dissipated in the large vein than in
smaller, antecubital veins in humans. In both instances,
capillaries are prominent components of the lesion.
The beneficial effects of the Vascular Wrap paclitaxel-
eluting mesh found in this study will need to be tested in
clinical trials. It is encouraging to note that recently similar
results with local paclitaxel delivery have been reported in
other animal models of access failure: in dogs using local
application of with an injectable copolymer, and in pigs
using ethylene vinyl acetate wraps.29,30 The dog study,
although supportive, was limited (only five animals) and
used histologic grading rather than quantitative analysis of
intimal hyperplasia at the venous anastomosis. Full results
of the pig study are not yet published, but paclitaxel caused
a significant reduction in luminal narrowing (0.1% vs con-
trol of 37.9%) with minimal local side effects. This study
used a nonabsorbable, paclitaxel-loaded ethylene vinyl ac-
etate wrap, which is a solid film that could prevent incor-
poration of the device into surrounding tissue and could
migrate out of position over time. Our method uses an
absorbable mesh, which allows incorporation and will re-
main in place more reliably. Furthermore, application of
the mesh is simple, and this material has met requirements
for human use, allowing clinical trials to start in the near
future.
Although the neointima found in our model closely
mimics that of humans, there are differences, as outlined.
Further, our study was only 8 weeks long, and it is not
known if the benefit seen at this time will translate into the
same long-lasting improvement in graft patency as it has for
drug-eluting coronary stents.18 The venous anastomosis of
dialysis grafts is subjected to chronic injury due to high
shear, turbulence, and contact with activated clotting fac-
tors released from the dialysis machine and from repeated
m the zero-dosemesh control and (right) 1.2g/mm2
TFE graft; N, neointima; T, thrombus; V, vein; and L,
n 5 fro
G, ePupstream cannulation. This chronic injury is not mitigated
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stabilization of the neointima during the early healing
process will make it less susceptible to chronic injury.
Long-term studies will be needed to determine if this
approach can significantly improve graft patency. However,
even an incremental improvement of patency would be
clinically important in the case of ePTFE access grafts,
which have an average patency of only 12 months.
Clinical implications. To date synthetic access grafts
do not function nearly as well as native vein fistulas, al-
though they have the clinical advantages of ease of place-
ment, early use, and easy cannulation. Intimal hyperplasia
at the venous end of ePTFE grafts is related to high flows,
turbulence, compliance mismatch, endothelial injury, and
platelet adhesion and activation at the site of injury. No
effective pharmacology has yet been developed that can
reduce intimal hyperplasia in the clinical setting.
Clinical trials with antiplatelet agents have failed to
provide significant improvement in patency. Saratin, which
inhibits platelet adhesion to the injured vascular wall, has
shown promise in a canine model of dialysis access failure31
but has not yet been tested in a clinical setting. Paclitaxel
holds great promise because it is one of the two drugs—
sirolimus32 being the other—that have proven benefit in
reduction of intimal hyperplasia after arterial injury in hu-
mans (ie, coronary angioplasty and stenting).
Improved patency of ePTFE access grafts would have a
tremendous effect on dialysis access, which is the bane of
long-term hemodialysis. The National Kidney Foundation
Kidney Diseases Outcome Quality Initiative recommends
that native arteriovenous fistulas be created when possible
and synthetic bypass, such as PTFE, be used as a last resort
owing to the inferior patency rate and increased risk of
infection.4 Any use of central venous catheters is discour-
aged because of their high complication rate. Unfortu-
nately, many patients have unsuitable veins for fistula cre-
ation. This problem is likely to increase as the population
develops more obesity and diabetes with resultant renal
failure. Synthetic grafts would be preferable to native vein
fistulas if their patency were as good because they are more
easily implanted and cannulated and can be used after only
a short period of maturation.
CONCLUSION
Application of the paclitaxel-eluting mesh to the ve-
nous anastomosis was highly effective in inhibiting the
neointimal growth that leads to arteriovenous graft stenosis
in this sheep model of dialysis access failure. This effect was
achieved without apparent toxicity to the adjacent vein.
These short-term, promising results in this animal model
will serve as a basis for longer-term, clinical studies to
determine if the Vascular Wrap paclitaxel eluting mesh can
durably improve the patency of ePTFE dialysis access
grafts.
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Dr Hugh A. Gelabert (Los Angeles, Calif). I wish to thank
the authors for kindly remitting a copy of their manuscript in a
timely manner. It is well written and clearly illustrated and for this
I commend them.
The success of drug eluting stents has provided the impetus for
this project, where drug-eluting mesh is used to modulate the
hyperplasia response in a sheep model of AV graft dialysis access.
An absorbable mesh was impregnated with paclitaxel (an agent
which inhibits angiogenesis and smooth muscle proliferation) and
this was wrapped around the venous anastomosis of a PTFE AV
graft. The animals were followed for about 2 months, then eutha-
nized.
The anastomoses were studied to assess diameter reduction
and histological characteristics. The findings indicate a statistically
significant reduction in the intimal hyperplasia at the venous anas-
tomosis in the treated subjects. Concerns include the small number
of subjects, the limited extent of the study period, and the limited
parameters studied in this experiment. Still the findings are encour-
aging and merit further investigation.
Question one, the authors indicate that paclitaxel has been
shown to inhibit neutrophil and lymphocyte activation, yet they
claim there was no dose effect on perigraft inflammation. Please
comment.
Question two, in the course of the experiment, five subjects
were lost, as their AV grafts clotted. Were any of the clotted grafts
subject to histological or morphometric analysis to assess intimal
hyperplasia in these failures?
Question three, given the described effects of paclitaxel—the
inhibition of neutrophils, lymphocytes, macrophages, smooth
muscle cells, and capillary growth—what is the chance of increased
prosthetic graft infections?
Dr Ted Kohler. Thank you Hugh, for a very thoughtful
review and for your excellent questions. First, regarding the effects
of paclitaxel on inflammation. We did note that there were fewer
macrophages associated with the wrap in the drug-treated groupsdose-effect escalation of these effects as the dose increased. This
either may be because our lowest dose was already producing the
maximum anti-inflammatory effect, or it could be related to the
rather crude qualitative measures we had for this effect, which was
not a primary focus of this study.
Next, with regard to the failed grafts, gross inspection deter-
mined a kink in one graft but no obvious cause of the failure of the
other devices. We have found that it is not possible to determine
the cause of failure using microscopic histology of clotted grafts:
the histology is too distorted by the thrombus. The neck of the
sheep is long and flexible, which makes these grafts prone to
kinking. Early on, we removed the external ring support of the
devices too far back from the venous anastomosis, and this may
have contributed to kinking. The relatively early timing of these
failures makes intimal hyperplasia an unlikely cause, and our find-
ing of reduced mural thrombus in the drug-treatment groups at 8
weeks makes primary thrombosis seem unlikely. The failure rate
the current experimental group was very similar to that we ob-
served in our initial description of this model. Further, there was
not a statistically significant difference between drug and control
groups, although the numbers are too small for valid statistical
comparison.
Finally, as far as I know, there have been no observations of
increased infections in any of the many applications of paclitaxel.
The slower resorption of the mesh along with inhibition of inflam-
mation could theoretically increase the risk of infection. One nice
aspect of this local approach is that the drug affects only a short
segment of the graft at the venous anastomosis, where infection is
rarely a problem. It is comforting to note that we did not observe
infections in our model, but the numbers are relatively small. The
drug is gone by a few weeks, so normal inflammatory processes
should resume by that time (hopefully not contributing to intimal
hyperplasia!). This question and the efficacy of this novel treatment
in patients will be addressed in a large clinical trial that is currently
being designed.
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I just have a question. I have to apologize for my ignorance, but
after the paclitaxel runs out, does it still confer protection against
development of neointimal hyperplasia? In other words, will both
groups start at the same rate after the paclitaxel runs out, and if so,
do you need to consider a better way to provide long-term protec-
tion with paclitaxel?
Dr Kohler. That is a great question. As I mentioned in the
coronary stent trials, patients maintain the benefit as long as 4 years
but that is a very different situation. In the coronary stent where
the neointima once it matures and perhaps endothelializes, then
the patient is no longer at risk, whereas in dialysis access grafts, as
we all know, there is an ongoing injury at that venous end. The
hope is that if the neointima can form, mature and become more
stable that it will be less prone to continue to stenose but that may
not be the case and that is why we need the longer-term studies.
Also, PTFE has such a poor patency rate that even if we could
get 6 or 8 months more out of this treatment, it would be a
significant difference and I think a clinically meaningful difference.
Wemay very well wish to go to a PTFE forearm loop before having
to go to a basilica transposition which is a much bigger deal for our
patients. With dialysis access, it is all about buying time.
Dr Watson.Do you know if there is a potential for longer time
paclitaxel elution? In other words, can you put something in that will
give the drug for a long period of time or does that have its own. . .Dr Kohler. There are local delivery devices that Steve (Han-
sen) has developed that could be used. The elution rate can be
adjusted with this bioresorbable but not beyond a couple of
months, so unless Rui Avelar has some trick up his sleeve that he
has not told me yet, I think we are going to be limited in that
respect.
Audience. That is a nice paper, Ted. I was going to ask you
about the elution kinetics as well. Can the PTFE actually elute the
paclitaxel? Is that an option rather than having the mesh be placed
externally and also bioabsorbable stents possibly or some variant of
that. How do you move from the model to a clinically practical
application?
Dr Kohler. Those are great thoughts as well. We have talked
about putting the drug directly into the PTFE.We are interested in
doing that in 60-micron PTFE grafts, which have a lot more space
within the graft material. The commercially available 20- to 30-
micron grafts do not have as much space within the intranodal
space to have drug, but it may be that having drug there is all we
need. I like the idea of the wrap around the vein because that is the
source for this neointima that is growing in. Actually the wrap is
extremely simple to use so in terms of clinical application I think
this is a extremely simple procedure to simply place the wrap and
that is what the next clinical trial is going to be, but we are always
thinking of other ways to deliver the drug.
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Schematic diagram of morphometric measurements. (ePTFE, Expanded polytetrafluoroethylene.)
Neointimal Area
Luminal Area
ePTFE Graft
% Stenosis = 100 x ( 1 -                           )Luminal Area
Graft Area
Where Luminal Area = Graft Area - (Neointimal Area + Mural Thrombus Area)
Mural Thrombus
Area
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Morphometric data for section 5, the first cross section of the graft distal to the venous anastomosis
Group Comparison Statistic
Neointimal area
(mm2)
Mural thrombus area
(mm2)
Luminal stenosis
(%)
Capillary density
(per mm2)
No mesh (n8) Mean  SD 10.5  6.8 2.6  1.9 49.4  22.4 11.9  5.8
Paclitaxel mesh
0.0 g/mm2 (n  7) Vs no mesh Mean  SD 6.4  3.2 3.8  2.9 40.9  14.1 8.9  5.6
FP test 1.151 0.907 0.21 1.082
P  .1 .1 .1 .1
P  N/A* N/A* N/A* N/A*
Wilcoxon P  .281 .3969 .8665 .281
0.3 g/mm2 (n  6) Vs mesh,
0.0 mg
Mean  SD 0.9  1.4 0.2  0.3 3.6  4.3 3.6  2.9
FP test 5.692 12.247 † 3.098
P  N/A* N/A* N/A* .01
P  .01 .01 .01 .024
Wilcoxon P  .0076 .0023 .0012 .0221
0.7 g/mm2 (n  8) Vs Mesh,
0.0 mg
Mean  SD 1.3  1.5 1.5  2.3 9.9  10.0 4.6  6.0
FP test 6.11 2.16 14.318 2.16
P  N/A* .025 N/A* .025
P  .01 .05 .01 .05
Wilcoxon P  .0037 .0709 .0012 .0693
1.2 g/mm2 (n  6) Vs Mesh,
0.0 mg
Mean  SD 1.2  1.4 0.6  1.2 6.8  5.6 1.1  1.7
FP test 5.692 5.196 † †
P  N/A* N/A* N/A* N/A*
P  .01 .01 .01 .01
Wilcoxon P  .0082 .0082 .0012 .0012
FP, Fligner-Policello; SD, standard deviation; N/A, not applicable.
Note that capillary density was measured in the neointima at the toe of the graft in sections 4 or 3, whichever had the best arc with the adjacent vein.
*Standard FP tables do not provide upper/lower bounds for these P values.
†When all data points in one sample are less than all data points in the other sample, the Fligner-Policello test results a statistic that tends to infinity (), and
therefore the P value tends to zero. Those differences are considered highly significant.
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Morphometric data for section 6, the second cross section of the graft distal to the venous anastomosis
Group Comparison Statistic Neointimal area (mm2) Mural thrombus area (mm2) Luminal stenosis (%)
No mesh (n  8) Mean  SD 1.9  2.4 6.3  6.4 35.7  28.5
Paclitaxel mesh
0.0 g/mm2 (n  7) Mean  SD 1.5  1.6 5.7  6.4 31.5  29.1
Vs no mesh FP test .161 .21 .323
P  .1 .1 .1
P  N/A* N/A* N/A*
Wilcoxon P  .8951 .8665 .7789
0.3 g/mm2 (n  6) Mean  SD 0.9  2.1 4.6  7.0 23.8  36.9
Vs mesh,
0.0 mg
FP test 1.561 .585 1.162
P  .05 .1 .1
P  .1 N/A* N/A*
Wilcoxon P  .1247 .5618 .2343
0.7 g/mm2 (n  8) Mean  SD .0  .0 .7  .7 3.3  3.5
Vs mesh,
0.0 mg
FP test 5.749 1.964 9.929
P  N/A* .025 n/a
P  .01 .05 .01
Wilcoxon P  .0014 .0709 .0012
1.2 g/mm2 (n  6) Mean  SD 0.0  0.0 0.5  0.7 1.9  3.0
Vs mesh,
0.0 mg
FP test 5.555 2.821 7.359
P  N/A* .01 N/A*
P  .01 .024 .01
Wilcoxon P  .0047 .0367 .0047
FP, Fligner-Policello; SD, standard deviation; N/A, not applicable.
*Standard FP tables do not provide upper/lower bounds for these P values.
